Cancer Science & Therapy

29^th Euro-Global Summit on Cancer Therapy & Radiation Oncology

July 23-25, 2018 | Rome, Italy

Scientific Tracks Abstracts

• Clonal cytogenetic abnormalities of undetermined significance

  Guilin Tang

  PDF HTML

• Clinical indications for mammography in men and correlation with breast cancer

  Kyungmin Shin

  PDF HTML

• Volumetric modulated arc (radio) therapy in pets treatment: The “La Cittadina Fondazione” experience

  Mario Dolera

  PDF HTML

• Combining 2D angiogenesis and 3D osteosarcoma microtissues to improve vascularization

  Hassan Chaddad

  PDF HTML

• The important overlapping problem between malign and benign thyroidal nodules in cancer patients with FDG-PET/CT

  Fikri Sekcuk Simsek and Yavuz Narin

  PDF HTML

• EGF and TGFα motogenic activities are mediated by the EGF receptor: Identification of the signaling pathways involved in oral cancer

  Aye Myat Thwe

  PDF HTML

• Role of free-base and metallated porphyrin derivatives promoting apoptosis as a consequence of cancer photodynamic therapy: Synthesis, characterization, and photobiological activities

  Devashish Sengupta

  PDF HTML

• Natural fluorescence for cancer diagnosis

  Aurelija Vaitkuviene and J V Vaitkus

  PDF HTML

• Applying Kochs postulates to test the cancer stem cell basis of cancer

  Christopher S Lange

  PDF HTML

• In vivo quantitation of circulating tumor cells with high-speed confocal microscopy in mouse tumor model

  Howon Seo

  PDF HTML

• A new disulfide-stabilized diabody against bFGF and the inhibition of cancer

  Ning Deng

  PDF HTML

• Through which pathway does trastuzumab and miR-122-5p combinatorial administration lead breast cancer cells to apoptosis: Intrinsic or extrinsic pathway

  Sercan Ergun

  PDF HTML

• Investigation of piR-36707 and piR-36741 expression levels in renal cell (transparent cell type) carcinomas

  Sercan Ergun, Diler Us Altay, Sezgin Gunes, Recep Buyukalpelli and Oguz Aydin

  PDF HTML

• Leptin receptor antagonist as a potent histone deacetylases (HDACs) inhibitor in ovarian cancer cells

  Ewa L Gregoraszczuk, K Zajda and E Fiedor

  PDF HTML

• Comparing BRAF mutation status in corresponding primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy

  Ibrahim Khalifeh

  PDF HTML

• Monitoring immune response in tumors

  Ibrahim Khalifeh

  PDF HTML

• Cancer stem cell marker EpCAM is involved in resistance to chemotherapy and poor prognosis in ovarian cancer patients

  Takeshi Motohara

  PDF HTML

• Selective Internal Radiation therapy (SIRT) in the Angiography Suite

  Grace Moscatelli

  PDF HTML

• Targeting the AKT/mTOR/STAT3 pathways through a ROS-dependent ubiquitin proteasome degradation in breast cancer by the natural polyphenol compound, carnosol

  Rabah Iratni, Hussain El Hasasna and Halima Al Samri

  PDF HTML

• The key to the riddle of the mechanism of most CVD and cancer is in arteriovenous anastomoses

  Vladimir Ivanovich Ermoshkin

  PDF HTML

• Cancer Stem Cells: How do we determine which cells they are?

  Christopher S Lange

  PDF HTML